Suppr超能文献

你无法免受在心脏代谢疾病中积累的神经酰胺的影响。

You aren't IMMUNE to the ceramides that accumulate in cardiometabolic disease.

机构信息

Department of Nutrition and Integrative Physiology, University of Utah, Salt Lake City, UT 94108, United States of America.

Department of Nutrition and Integrative Physiology, University of Utah, Salt Lake City, UT 94108, United States of America.

出版信息

Biochim Biophys Acta Mol Cell Biol Lipids. 2022 Jun;1867(6):159125. doi: 10.1016/j.bbalip.2022.159125. Epub 2022 Feb 23.

Abstract

Obesity leads to persistent increases in immune responses that contribute to cardiometabolic pathologies such as diabetes and cardiovascular disease. Pro-inflammatory macrophages infiltrate the expanding fat mass, which leads to increased production of cytokines such as tumor necrosis factor-alpha. Moreover, saturated fatty acids enhance signaling through the toll-like receptors involved in innate immunity. Herein we discuss the evidence that ceramides-which are intermediates in the biosynthetic pathway that produces sphingolipids-are essential intermediates that link these inflammatory signals to impaired tissue function. We discuss the mechanisms linking these immune insults to ceramide production and review the numerous ceramide actions that alter cellular metabolism, induce oxidative stress, and stimulate apoptosis. Lastly, we evaluate the correlation of ceramides in humans with inflammation-linked cardiometabolic disease and discuss preclinical studies which suggest that ceramide-lowering interventions may be an effective strategy to treat or prevent such maladies.

摘要

肥胖会导致免疫反应持续增加,从而导致糖尿病和心血管疾病等代谢性疾病。促炎巨噬细胞浸润扩张的脂肪组织,导致细胞因子如肿瘤坏死因子-α的产生增加。此外,饱和脂肪酸增强了参与先天免疫的 toll 样受体的信号转导。本文讨论了证据表明,神经酰胺 - 是生物合成途径产生鞘脂的中间产物 - 是将这些炎症信号与组织功能障碍联系起来的必要中间产物。我们讨论了将这些免疫损伤与神经酰胺产生联系起来的机制,并回顾了许多改变细胞代谢、诱导氧化应激和刺激细胞凋亡的神经酰胺作用。最后,我们评估了人类神经酰胺与炎症相关的代谢性疾病的相关性,并讨论了临床前研究,这些研究表明,降低神经酰胺的干预可能是治疗或预防这些疾病的有效策略。

相似文献

1
You aren't IMMUNE to the ceramides that accumulate in cardiometabolic disease.
Biochim Biophys Acta Mol Cell Biol Lipids. 2022 Jun;1867(6):159125. doi: 10.1016/j.bbalip.2022.159125. Epub 2022 Feb 23.
2
Ceramides are fuel gauges on the drive to cardiometabolic disease.
Physiol Rev. 2024 Jul 1;104(3):1061-1119. doi: 10.1152/physrev.00008.2023. Epub 2024 Feb 1.
3
Ceramides and other sphingolipids as drivers of cardiovascular disease.
Nat Rev Cardiol. 2021 Oct;18(10):701-711. doi: 10.1038/s41569-021-00536-1. Epub 2021 Mar 26.
4
Ceramide Metabolism in Cardiovascular Disease: A Network With High Therapeutic Potential.
Arterioscler Thromb Vasc Biol. 2022 Oct;42(10):1220-1228. doi: 10.1161/ATVBAHA.122.318048. Epub 2022 Aug 25.
5
Ceramide microdomains: the major influencers of the sphingolipid media platform.
Biochem Soc Trans. 2024 Aug 28;52(4):1765-1776. doi: 10.1042/BST20231395.
6
Contribution of specific ceramides to obesity-associated metabolic diseases.
Cell Mol Life Sci. 2022 Jul 5;79(8):395. doi: 10.1007/s00018-022-04401-3.
7
Roles of Ceramides and Other Sphingolipids in Immune Cell Function and Inflammation.
Adv Exp Med Biol. 2019;1161:169-191. doi: 10.1007/978-3-030-21735-8_15.
8
Sphingolipids as a Culprit of Mitochondrial Dysfunction in Insulin Resistance and Type 2 Diabetes.
Front Endocrinol (Lausanne). 2021 Mar 18;12:635175. doi: 10.3389/fendo.2021.635175. eCollection 2021.
10
Ceramides - Lipotoxic Inducers of Metabolic Disorders.
Trends Endocrinol Metab. 2015 Oct;26(10):538-550. doi: 10.1016/j.tem.2015.07.006.

引用本文的文献

1
Ceramide signaling in immunity: a molecular perspective.
Lipids Health Dis. 2025 Jul 1;24(1):225. doi: 10.1186/s12944-025-02642-2.
3
Glycosylation of ceramide synthase 6 is required for its activity.
J Lipid Res. 2025 Jan;66(1):100715. doi: 10.1016/j.jlr.2024.100715. Epub 2024 Nov 26.
5
Myocardial Fibrosis and Steatosis in Patients with Aortic Stenosis: Roles of Myostatin and Ceramides.
Int J Mol Sci. 2023 Oct 24;24(21):15508. doi: 10.3390/ijms242115508.
6
Circulating Sphingolipids in Insulin Resistance, Diabetes and Associated Complications.
Int J Mol Sci. 2023 Sep 13;24(18):14015. doi: 10.3390/ijms241814015.

本文引用的文献

1
Unwrapping the mechanisms of ceramide and fatty acid-initiated signals leading to immune-inflammatory responses in obesity.
Int J Biochem Cell Biol. 2021 Jun;135:105972. doi: 10.1016/j.biocel.2021.105972. Epub 2021 Apr 14.
2
Ceramides and other sphingolipids as drivers of cardiovascular disease.
Nat Rev Cardiol. 2021 Oct;18(10):701-711. doi: 10.1038/s41569-021-00536-1. Epub 2021 Mar 26.
3
Neutral sphingomyelinase-2 and cardiometabolic diseases.
Obes Rev. 2021 Aug;22(8):e13248. doi: 10.1111/obr.13248. Epub 2021 Mar 18.
4
Keep Your Friends Close, but Your Enemies Closer: Role of Acid Sphingomyelinase During Infection and Host Response.
Front Med (Lausanne). 2021 Jan 21;7:616500. doi: 10.3389/fmed.2020.616500. eCollection 2020.
5
Cardiomyocyte Krüppel-Like Factor 5 Promotes De Novo Ceramide Biosynthesis and Contributes to Eccentric Remodeling in Ischemic Cardiomyopathy.
Circulation. 2021 Mar 16;143(11):1139-1156. doi: 10.1161/CIRCULATIONAHA.120.047420. Epub 2021 Jan 12.
6
Ceramides are necessary and sufficient for diet-induced impairment of thermogenic adipocytes.
Mol Metab. 2021 Mar;45:101145. doi: 10.1016/j.molmet.2020.101145. Epub 2020 Dec 19.
7
Sphingomyelinases and Liver Diseases.
Biomolecules. 2020 Oct 30;10(11):1497. doi: 10.3390/biom10111497.
8
Adipocyte Ceramides-The Nexus of Inflammation and Metabolic Disease.
Front Immunol. 2020 Sep 23;11:576347. doi: 10.3389/fimmu.2020.576347. eCollection 2020.
9
Metabolic Messengers: ceramides.
Nat Metab. 2019 Nov;1(11):1051-1058. doi: 10.1038/s42255-019-0134-8. Epub 2019 Oct 24.
10
An adiponectin-S1P autocrine axis protects skeletal muscle cells from palmitate-induced cell death.
Lipids Health Dis. 2020 Jul 1;19(1):156. doi: 10.1186/s12944-020-01332-5.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验